FindTrial
Sign In

Traditional Chinese medicine in the treatment of systemic lupus erythematosus: a prospective cohort study

Traditional Chinese medicine in the treatment of systemic lupus erythematosus: a prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000003114
Enrollment
Unknown
Registered
2020-03-15
Start date
2020-03-12
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

experimental group vs control group:conbined treatment of traditional chinese medicine and western medicine vs. western medicine

Sponsors

The Second Affiliated Hospital of Zhejiang Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Conforms to the SLE classification standard formulated by SLICC in 2009; 2. Aged between 14 and 65; 3. The patient was informed and agreed to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with end-stage renal disease, grade IV heart failure (NYHA classification), liver failure, sepsis, and malignant tumors; 2. Patients with severe or poorly controlled hypertension (SBP >= 160mmHg or DBP>= 90mmHg) or diabetes (HbA1c> 8%); 3. Schizophrenia or other mental illness patients who cannot fully recognize their behavior; 4. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
SLEDAI score;—

Secondary

MeasureTime frame
Incidence of infection;Disease recurrence rate;TCM syndrome score;LupusHoL scale;Glucocorticoid dosage;Systemic lupus erythematosus cumulative organ damage index;—

Countries

China

Contacts

Public ContactWang Xinchang

The Second Affiliated Hospital of Zhejiang Chinese Medicine University

ossani@126.com+86 13065714635

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026